Impact of Age on the Outcome of Pulmonary Vein Isolation for Atrial Fibrillation Using Circular Mapping Technique and Cooled‐Tip Ablation Catheter:

作者
Mandeep Bhargava,Nassir Marrouche,David O. Martin,Robert A. Schweikert,Walid I. Saliba,Eduardo Saad,Dianna Bash,Michelle Williams‐Andrews,Antonio Rossillo,Demet Erciyes,Yaariv Khaykin,J. David Burkhardt,George Joseph,Patrick Tchou,Andrea Natale
出处
期刊:Journal of Cardiovascular Electrophysiology [Wiley]
卷期号:15 (1): 8-13 被引量:110
标识
DOI:10.1046/j.1540-8167.2004.03266.x
摘要

INTRODUCTION: A retrospective analysis was performed to define the impact of age on the outcomes and complications in patients undergoing pulmonary vein isolation (PVI). PVI is an evolving technique for the management of atrial fibrillation (AF). The impact of age on the risks, outcomes, and complications of PVI has not been well defined. METHODS AND RESULTS: A total of 323 patients (259 men and 64 women; age 18-79 years) underwent PVI for treatment of drug-refractory symptomatic AF. An ostial isolation of the pulmonary veins was done using a cooled-tip ablation catheter guided by circular mapping. The patients were divided into three groups based on age (group I: <50 years, group II: 51-60 years, group III: >60 years) and the results were compared. There were 106 patients in group I, 114 patients in group II, and 103 patients in group III (mean age 41.3 +/- 7.8 years, 55.4 +/- 2.75 years, and 66.6 +/- 4.18 years, respectively) who underwent PVI for paroxysmal (53.8%), persistent (10.8%), or permanent (35.3%) AF. Baseline characteristics were similar except for a higher prevalence of hypertension and/or structural heart disease in groups II and III (58% and 63% vs 33% in group I, respectively). The procedural variables were similar in all age groups. The overall risk of complications was similar in the three groups, except that the risk of stroke was significantly higher in patients >60 years of age (3% vs 0%; P < 0.05). The recurrence rates of AF were similar in the three age groups (15.1%, 16.7%, and 18.4%, respectively; P > 0.05). The risk of severe pulmonary vein stenosis (1.8%, 2.6%, and 0.9%, respectively) was low and did not vary with age. CONCLUSION: PVI is a safe and effective treatment for patients with drug-refractory symptomatic AF, and its benefits extend to all age groups. The risk of procedural complications, especially thromboembolic events, appears to be higher in the elderly age group. This observation needs to be considered while assessing potential candidates for the procedure.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
橙子橙完成签到,获得积分10
2秒前
枫威完成签到 ,获得积分10
3秒前
crown完成签到,获得积分10
5秒前
6秒前
枯木逢春完成签到 ,获得积分10
9秒前
行走发布了新的文献求助10
13秒前
18秒前
pmsl完成签到,获得积分10
19秒前
spring完成签到,获得积分10
19秒前
小超发布了新的文献求助10
22秒前
闫佳美完成签到,获得积分10
23秒前
内向鼠标完成签到 ,获得积分10
23秒前
合适乐巧完成签到 ,获得积分10
33秒前
william完成签到,获得积分10
33秒前
37秒前
38秒前
lc完成签到 ,获得积分10
40秒前
执意完成签到 ,获得积分10
40秒前
hezhiling发布了新的文献求助10
41秒前
april95完成签到 ,获得积分10
41秒前
谢文强完成签到,获得积分10
43秒前
王兵发布了新的文献求助10
43秒前
wanci应助joinn采纳,获得10
47秒前
111完成签到,获得积分10
48秒前
兼听则明完成签到,获得积分10
57秒前
李健的小迷弟应助hezhiling采纳,获得10
58秒前
能干的飞荷完成签到,获得积分10
1分钟前
大雪完成签到 ,获得积分10
1分钟前
完美世界应助科研通管家采纳,获得20
1分钟前
柒柒完成签到,获得积分10
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
dde应助科研通管家采纳,获得10
1分钟前
dde应助科研通管家采纳,获得10
1分钟前
科研通AI6.4应助joinn采纳,获得10
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
cdercder应助科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
基于锂离子电池正极材料回收的绿色溶剂开发及工程化应用研究 500
Auslegungsgeschichte 500
Transdermal drug delivery systems market size report 500
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7640634
求助须知:如何正确求助?哪些是违规求助? 9213678
关于积分的说明 19763709
捐赠科研通 7206459
什么是DOI,文献DOI怎么找? 3276117
关于科研通互助平台的介绍 2437790
邀请新用户注册赠送积分活动 2273562